Platelet-rich plasma(PRP), is a concentrate of platelet-rich plasma protein derived from whole blood. The main components of it are platelets, leukocytes and fibrin. Autologous PRP treatment can avoid the immune rejection caused by exogenous growth factor and the spread of disease. Evidence of the efficacy and safety of PRP has been proven in many studies. Bronchopleural fistula (BPF) represents a challenging clinical entity characterized by abnormal communication between the bronchial tree and the pleural space. Respiratory intervention has become one of the most common treatments to fight the disease. Although the short-term occlusion effect of conventional treatment methods of respiratory intervention is relatively easy to achieve, there is great uncertainty in the long-term treatment effect, and long-term large fistulas have little chance of healing. PRP has shown significant efficacy for hyperplastic scar of skin. Correspondingly, PRP will be applied as treatment of BPF to cure fistula.

Inclusion Criteria:

• Subjects with aged between 18 to 75
• Subjects diagnosed with bronchopleural fistula (the sizes of the fistulas less than 4mm)
• Subjects willing to accept PRP treatment

Exclusion Criteria:

• Subjects with fistulas larger than 4mm
• Subjects who cannot tolerate bronchoscopy due to severe cardiac disease or other major comorbidities
• Pregnant or breastfeeding women